#USA #San Francisco #Convergent Therapeutics #Prostate Cancer #CONV01-α

Convergent Therapeutics Delivers Key Clinical Updates at ASCO 2025

Convergent Therapeutics Inc., a pioneer in clinical-stage biotechnology focused on developing advanced radiopharmaceutical treatments for cancer, made headlines at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025. The company presented key clinical trial updates regarding its flagship product, CONV01-α (225Ac-J591), which is specifically designed to target the prostate-specific membrane antigen (PSMA).

Clinical Trial Highlights

The initial presentation, titled "Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-IT in advanced prostate cancer," showcased notable findings from a Phase I dose-escalation trial. This trial assessed the efficacy of adding CONV01-α to the well-established treatment 177Lu-PSMA-IT in patients suffering from progressive metastatic castration-resistant prostate cancer (mCRPC). A total of 18 participants were included in the study, divided into three groups based on the dosage of CONV01-α administered.

The results were promising, revealing a median overall survival rate of 29.8 months. At the time the data were compiled, ten participants remained alive, indicating the drug's effectiveness. Notably, five individuals experienced no progression in prostate-specific antigen (PSA) levels after one year, with one patient remaining progression-free for a remarkable 34 months without active therapy. These findings underscore the potential of CONV01-α, with a significant 94% of patients showing decreased PSA levels and 28% achieving a PSA90 response. Furthermore, 80% of patients whose circulating tumor cell count was assessed transitioned from a "unfavorable" to a "favorable" category, demonstrating the drug's positive impact on tumor dynamics.

Dr. Neil Bander, Co-Founder and Chief Scientific Officer of Convergent Therapeutics, emphasized the seriousness of the results, noting that the impressive clinical activity aligns with pre-clinical data that suggest a synergistic effect when the antibody and ligand are combined. He highlighted the potential for patients to undergo additional treatment cycles due to the benign safety profile observed in the trial, which reported few high-grade adverse events.

Future Directions

The second presentation at the symposium, named "CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer," addressed ongoing trials evaluating CONV01-α's safety and effectiveness as a standalone therapy. Philip Kantoff, Co-Founder and CEO, stated that the CONVERGE-01 trial aims to validate the encouraging high response rate and durability observed in earlier studies, paving the way for crucial pivotal trials.

Understanding CONV01-α

CONV01-α offers a sophisticated solution by combining the precision of antibodies with the lethal potential of alpha-emitting radionuclides. The humanized monoclonal antibody targets PSMA, a marker often overexpressed in prostate cancer cells. The incorporation of the radionuclide Ac-225 enables the release of high-energy alpha particles specifically within the cancer cells' vicinity, effectively hurting the cells while sparing healthy tissues from unnecessary radiation.

Convergent's innovative approach positions them at the forefront of cancer treatment, particularly as they advance into the CONVERGE-01 Phase II trial focused on establishing the robustness and safety of CONV01-α in the treatment landscape. By blending potent localized radiation with targeted therapeutics, Convergent Therapeutics continues to strive towards enhancing patient outcomes in oncology.

For further updates and details on clinical trials, visit Convergent Therapeutics and follow their developments on social media platforms.